Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization Timeline Change
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1257)
•••
Comment by CancerSlayeron Feb 17, 2022 9:58pm
676 Views
Post# 34440518

RE:RE:RE:RE:RE:RE:Commercialization Timeline Change

RE:RE:RE:RE:RE:RE:Commercialization Timeline Change
O12009 wrote:

 

CancerSlayer wrote: Or, & more likely....the "commercialization phase" timeline (starting early 2023) may simply represent business planning/strategizing for a future commercial roll-out (I.e. feasibility, costs, price point, etc.) prior to actual market approval (projected to be mid-end of 2025).

 

 


In the past when we find out new information we always go back to prior news releases and there it is spelled out. So I don't think it's a mistake when they say January 2023 and they leave out that's with a partner. This should make for a fantastic news release. 


 

I wouldn't mind catching that Big Fish in the upstream as long as it spawns plenty of commercial & shareholder success in the downstream.  Expecting good news, but I'll take fantastic.  Good luck.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities